Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy

Polskie Archiwum Medycyny Wewnetrznej

Volumn 120, Issue 9, 2010, Pages 334-340

  Za̧bczyk, Michał ^a   Butenas, Saulius ^b   Palka, Ilona ^c   Nessler, Jadwiga ^a,c   Undas, Anetta ^a,c  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF VERMONT   (United States)

^c Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Activated factor XI; Coronary artery disease; Systolic heart failure; Thrombin generation; Tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 11A; THROMBOPLASTIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HEART RIGHT VENTRICLE PRESSURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; SYSTOLIC HEART FAILURE; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; CARDIOMYOPATHY; METABOLISM; MIDDLE AGED;

AGED; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARDIOMYOPATHIES; FACTOR XA; FACTOR XIA; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION;

EID: 79951957565     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.961     Document Type: Article

References (22)

1. Butenas S, Undas A, Gissel MT, et al. Factor XIa and tissue factor activity in patients with coronary artery disease. Thromb Haemost. 2008; 99: 142-149.
2. Kim HK, Song KS, Park YS, et al. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease. Cardiology. 2000; 93: 31-36. (Pubitemid 30436408)
3. Minnema MC, Peters RJ, de Winter R, et al. Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2000; 20: 2489-2493.
4. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992; 116: 1-5.
5. Freudenberger RS, Hellkamp AS, Halperin JL, et al. SCD-HeFT Investigators. Risk of Thromboembolism in Heart Failure An Analysis From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2007; 115: 2637-2641.
6. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995; 92: 657-671.
7. Edgington TS, Dickinson CD, Ruf W. The structural basis of function of the TF. VIIa complex in the cellular initiation of coagulation. Thromb Haemost. 1997; 78: 401-405.
8. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004; 24: 1015-1022. (Pubitemid 38737825)
9. Seligsohn U. Factor XI in haemostasis and thrombosis: past, present and future. Thromb Haemost. 2007; 98: 84-89. (Pubitemid 47074182)
10. Kannemeier C, Shibamiya A, Nakazawa F, et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A. 2007; 104: 6388-6393. (Pubitemid 47186104)
11. Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest. 1997; 99: 2323-2327.
12. Steppich BA, Braun SL, Stein A, et al. TF activity predicts cardiovascular mortality in patients with acute myocardial infarction. Thromb J. 2009; 7: 11.
13. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005; 111: 3481-3488. (Pubitemid 40923403)
14. Kaikita K, Ogawa H, Yasue H, et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol. 1997; 17: 2232-2237. (Pubitemid 28057126)
15. Siegemund A, Petros S, Siegemund T, et al. The endogenous thrombin potential and high levels of coagulation factor VIII, factor IX and factor XI. Blood Coagul Fibrinolysis. 2004; 15: 241-244. (Pubitemid 38561551)
16. Cushman M, O'Meara ES, Folsom AR, Heckbert SR. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. Blood. 2009; 114: 2878-2883.
17. Merlo C, Wuillemin WA, Redondo M, et al. Elevated levels of plasma prekallikrein, high molecular weight kininogen and factor XI in coronary heart disease. Atherosclerosis. 2002; 161: 261-267. (Pubitemid 34219178)
18. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008; 29: 2388-2442.
19. Sharma ND, McCullough PA, Philbin EF, Weaver WD. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest. 2000; 117: 314-320. (Pubitemid 30111577)
20. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: potentially pathogenic agents and diagnostic markers. Transfus Med Rev. 2006; 20: 1-26. (Pubitemid 41811224)
21. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 1993; 81: 734-744. (Pubitemid 23040866)
22. Mallat Z, Benamer H, Hugel B, et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation. 2000; 101: 841-843. (Pubitemid 30117876)